Bortezomib

• Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended
  2022-500584-12-00 Phase II 2 countries University Hospital Of Ulm AöR
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended
  2023-505219-19-00 Phase I/II 6 countries Celgene Corp.
• A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended
  2024-511781-37-00 Phase II 3 countries Ceska Myelomova Skupina z.s.; Emn Trial Office S.r.l. Impresa Sociale; European …
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended
  2023-506125-10-00 Phase III 11 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended
  2024-516905-22-00 Phase III 1 country Fundacion PETHEMA
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended
  2024-513464-26-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended
  2024-512049-17-00 Phase IV 1 country Universita' Degli Studi Di Torino
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended
  2024-513070-21-00 Phase II 11 countries Charite Universitaetsmedizin Berlin KöR
• Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bor… Ended
  2023-506110-43-00 Phase I/II 3 countries AbbVie Deutschland GmbH & Co. KG
• A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl… Ended
  2024-514417-34-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 Phase II 1 country Fundacion Pethema
• An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e… Ended
  2024-516130-35-00 Phase II 1 country Fundacion Pethema
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended
  2024-516300-41-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended
  2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
• Seamless Phase 2/3 Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma Ended
  2023-503618-64-00 Phase II 3 countries Janssen - Cilag International
• A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai… Ended
  2024-516061-36-00 Phase II 1 country Hellenic Society Of Hematology
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac… Ended
  2024-511066-36-00 Phase III 14 countries Prothena Biosciences Limited
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended
  2023-507312-13-00 Phase III 6 countries Janssen - Cilag International
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha… Ended
  2024-511967-26-00 Phase III 11 countries Janssen Cilag International
• STRENSIQ® Immunogenicity Study Ended
  2022-502793-17-00 Phase IV 1 country Alexion Pharmaceuticals Inc.

Showing 49–70 of 70 trials